Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02242032 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
A Phase 1 study, sponsored by Parion Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT02242032: Completed Phase 1 study, sponsored by Parion Sciences.
NCT02242032 is a Phase 1 study that has completed, run by Parion Sciences. The registered enrollment target is 53 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02242032, a Phase 1 study, has completed, sponsored by Parion Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.
Primary Outcome
One primary objective of this trial is to assess the safety of P-321 Ophthalmic Solution versus placebo in subjects with moderate dry eye disease at 14 days (Cohorts 1-4) and 28 days (Cohort 4 only).
Interventions
- DRUG P-321 Ophthalmic Solution
- DRUG P-321 Ophthalmic Solution placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
What the finished NCT02242032 record still lists
NCT02242032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 2 interventions - of which P-321 Ophthalmic Solution is the first listed.
NCT02242032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02242032 about?
NCT02242032 is a clinical study titled "Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease". The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.
What is the current status of trial NCT02242032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2014-07. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02242032?
The interventions under investigation include: P-321 Ophthalmic Solution (DRUG), P-321 Ophthalmic Solution placebo (DRUG).
Who is sponsoring clinical trial NCT02242032?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02242032's enrollment target sits among peer trials
53 948th of 2000 higher than 1,045 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia